The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction.

Trial Profile

The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Anakinra (Primary)
  • Indications Glucose intolerance
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 26 Sep 2013 Primary endpoint 'Insulin-levels' has been met.
    • 23 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top